Lobbying disclosures · Lobbying report
BMRN: second_quarter 2017 lobbying report
Orphan drugs and rare diseases, matters related to drug reimbursement policy. Orphan drugs and rare disease matters
Follow BMRN- Became public
- Jul 6, 2026, 9:24 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 3:19 PM EST
Why this is connected
Exact legal-name match: BIOMARIN PHARMACEUTICAL INC (https://www.sec.gov/Archives/edgar/data/1048477/).
Reported lobbying amounts
Income: $30,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/7bc4486e-c2bd-4f04-a0ea-9b2879aad364/","filing_uuid":"7bc4486e-c2bd-4f04-a0ea-9b2879aad364","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2017,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7bc4486e-c2bd-4f04-a0ea-9b2879aad364/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jay Engleson","dt_posted":"2026-07-06T09:24:23-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"750 9TH STREET STE 650","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":65191,"url":"https://lda.gov/api/v1/registrants/65191/","house_registrant_id":35579,"name":"VENN STRATEGIES","description":"A political and public affairs consulting firm.","address_1":"750 9th St NW, Suite 650","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAY ENGLESON","contact_telephone":"+1 301-509-9933","dt_updated":"2026-08-29T15:03:26.607563-04:00"},"client":{"id":162768,"url":"https://lda.gov/api/v1/clients/162768/","client_id":1003480,"name":"BIOMARIN PHARMACEUTICAL, INC.","general_description":"Develops & commercializes innovative biopharmaceuticals for serious diseases","client_government_entity":false,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-12-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Orphan drugs and rare diseases, matters related to drug reimbursement policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":25887,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"SILVERMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58095,"prefix":null,"prefix_display":null,"first_name":"TIM","nickname":null,"middle_name":null,"last_name":"CAREY","suffix":null,"suffix_display":null},"covered_position":"Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA","new":false},{"lobbyist":{"id":61934,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"LEE","suffix":null,"suffix_display":null},"covered_position":"Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin","new":false},{"lobbyist":{"id":64837,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SPIRA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO)","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Orphan drugs and rare disease matters","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":25887,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"SILVERMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58095,"prefix":null,"prefix_display":null,"first_name":"TIM","nickname":null,"middle_name":null,"last_name":"CAREY","suffix":null,"suffix_display":null},"covered_position":"Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA","new":false},{"lobbyist":{"id":61934,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"LEE","suffix":null,"suffix_display":null},"covered_position":"Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin","new":false},{"lobbyist":{"id":64837,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SPIRA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BMRN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold BioMarin Pharmaceutical BMRN
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.